Advertisement

Topics

Fibrogen Company Profile

16:41 EST 15th December 2018 | BioPortfolio

Extracellular matrix biology to discover and develop innovative therapies for fibroproliferative disorders - organ fibrosis, tissue repair and regeneration.

Location

225 Gateway Boulevard
South San Francisco
CA
94080
United States of America

Contact

Phone: 415 635 1500
Fax: 650 866 7204
Email: hr@fibrogen.com


News Articles [26 Associated News Articles listed on BioPortfolio]

FibroGen completes enrolment in Phase lll programme of roxadustat

FibroGen has completed enrolling patients in a Phase lll trial programme that aims to evaluate the use of roxadustat for...Read More... The post FibroGen completes enrolment in Phase lll programme of ...

FDA fast-tracks FibroGen's idiopathic pulmonary fibrosis therapy

FibroGen's pamrevlumab, being developed to treat patients with idiopathic pulmonary fibrosis, was granted fast-track designat -More- 

FibroGen Announces Completion of Enrollment in U.S. Phase 3 Clinical Program for Roxadustat

FibroGen (NASDAQ:FGEN), a biopharmaceutical company, today announced the completion of patient enrollment in the Phase 3 studies supporting the U.S. new drug application (NDA) submission for roxadusta...

FibroGen Appoints Maykin Ho, Ph.D., to Board of Directors

SAN FRANCISCO, Dec. 06, 2018 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN), a leading biopharmaceutical company discovering and developing a pipeline of first-in-class therapeutics, today annou...

FibroGen Reports Third Quarter 2018 Financial Results

—Roxadustat New Drug Applications under Review in China and Japan——Phase 3 Clinical Trials in IPF and Pancreatic Cancer to Initiate in First Quarter 2019——Conference Call Today at 5:00 p.m....

FibroGen Reports Second Quarter 2018 Financial Results

Roxadustat U.S. Phase 3 Topline Clinical Data Readout on Track for Fourth Quarter of 2018 Feedback from FDA on Pamrevlumab Pivotal Programs in IPF and in Locally Advanced Unresectable Pancreatic Ca...

FibroGen's pamrevlumab improves survival in Phase I/II for pancreatic cancer

FibroGen, Inc. (FGEN) CEO Thomas Neff on Q2 2018 Results - Earnings Call Transcript

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [2 Associated Clinical Trials listed on BioPortfolio]

Compassionate Single Subject Use of FG-3019 (FibroGen) in Locally Advanced, Unresectable Pancreatic Cancer

Single compassionate use subject is an 83 year old woman with a history of lymph node positive breast cancer and recently diagnosed pancreatic cancer in May. With an Eastern Cooperative On...

The Relationship Between Arterial Stiffness and Respiratory Failure in Motor Neurone Disease

- Patients with Motor Neurone Disease (MND) admitted to Lane Fox Unit /Royal Brompton Hospital and/or reviewed in Lane Fox Unit /Royal Brompton Hospital clinics and/or outreach ...

Companies [2 Associated Companies listed on BioPortfolio]

FibroGen, Inc.

FibroGen, Inc. is a biotechnology-based drug discovery company using its expertise in the fields of tissue fibrosis, connective tissue growth factor (CTGF), and hypoxia-inducible ...

Fibrogen

Extracellular matrix biology to discover and develop innovative therapies for fibroproliferative disorders - organ fibrosis, tissue repair and regeneration.

More Information about "Fibrogen" on BioPortfolio

We have published hundreds of Fibrogen news stories on BioPortfolio along with dozens of Fibrogen Clinical Trials and PubMed Articles about Fibrogen for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Fibrogen Companies in our database. You can also find out about relevant Fibrogen Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks



Searches Linking to this Company Record